nuvation bio - NUVB

NUVB

Close Chg Chg %
2.94 0.02 0.51%

Pre-Market

2.95

+0.02 (0.51%)

Volume: 2.52M

Last Updated:

Nov 13, 2024, 3:59 PM EDT

Company Overview: nuvation bio - NUVB

NUVB Key Data

Open

$2.93

Day Range

2.93 - 3.07

52 Week Range

1.21 - 4.16

Market Cap

$989.07M

Shares Outstanding

337.57M

Public Float

229.11M

Beta

1.36

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.17

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.85M

 

NUVB Performance

1 Week
 
1.74%
 
1 Month
 
29.07%
 
3 Months
 
7.33%
 
1 Year
 
112.32%
 
5 Years
 
N/A
 

NUVB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About nuvation bio - NUVB

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

NUVB At a Glance

Nuvation Bio, Inc.
1500 Broadway
New York, New York 10036
Phone 1-332-208-6102 Revenue 0.00
Industry Biotechnology Net Income -75,802,000.00
Sector Health Technology Employees 51
Fiscal Year-end 12 / 2024
View SEC Filings

NUVB Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.547
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 2.778
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.014

NUVB Efficiency

Revenue/Employee N/A
Income Per Employee -1,486,313.725
Receivables Turnover N/A
Total Asset Turnover N/A

NUVB Liquidity

Current Ratio 44.113
Quick Ratio 44.113
Cash Ratio 43.739

NUVB Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -11.719
Return on Equity -12.03
Return on Total Capital -12.444
Return on Invested Capital -11.982

NUVB Capital Structure

Total Debt to Total Equity 0.662
Total Debt to Total Capital 0.658
Total Debt to Total Assets 0.645
Long-Term Debt to Equity 0.336
Long-Term Debt to Total Capital 0.334
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nuvation Bio - NUVB

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- 368.00K 484.00K 222.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 368.00K 484.00K 222.00K
Depreciation
- 368.00K 484.00K 222.00K
Amortization of Intangibles
- - - -
-
COGS Growth
- - +31.52% -54.13%
-
Gross Income
- (368.00K) (484.00K) (222.00K)
Gross Income Growth
- - -31.52% +54.13%
-
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
3.06M 92.95M 119.25M 99.60M
Research & Development
- 69.04M 87.81M 71.29M
Other SG&A
3.06M 23.91M 31.43M 28.31M
SGA Growth
- +2,936.14% +28.29% -16.48%
Other Operating Expense
- - - -
-
Unusual Expense
15.16M (4.23M) (10.19M) (497.00K)
EBIT after Unusual Expense
(18.23M) (89.09M) (109.55M) (99.33M)
Non Operating Income/Expense
7.01K 2.24M 5.35M 23.52M
Non-Operating Interest Income
7.01K 2.96M 7.45M 24.61M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(18.22M) (86.85M) (104.20M) (75.80M)
Pretax Income Growth
- -376.68% -19.98% +27.25%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(18.22M) (86.85M) (104.20M) (75.80M)
Minority Interest Expense
- - - -
-
Net Income
(18.22M) (86.85M) (104.20M) (75.80M)
Net Income Growth
- -376.68% -19.98% +27.25%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(18.22M) (86.85M) (104.20M) (75.80M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(18.22M) (86.85M) (104.20M) (75.80M)
EPS (Basic)
-0.9872 -0.4389 -0.4808 -0.3463
EPS (Basic) Growth
- +55.54% -9.55% +27.97%
Basic Shares Outstanding
18.46M 197.89M 216.72M 218.88M
EPS (Diluted)
-0.9872 -0.4389 -0.4808 -0.3463
EPS (Diluted) Growth
- +55.54% -9.55% +27.97%
Diluted Shares Outstanding
18.46M 197.89M 216.72M 218.88M
EBITDA
(3.06M) (92.95M) (119.25M) (99.60M)
EBITDA Growth
- -2,936.14% -28.29% +16.48%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 6.75
Number of Ratings 5 Current Quarters Estimate -0.136
FY Report Date 12 / 2024 Current Year's Estimate -2.162
Last Quarter’s Earnings -0.15 Median PE on CY Estimate N/A
Year Ago Earnings -0.35 Next Fiscal Year Estimate -0.612
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 3 5 5
Mean Estimate -0.14 -0.15 -2.16 -0.61
High Estimates -0.10 -0.13 -1.98 -0.52
Low Estimate -0.17 -0.16 -2.27 -0.68
Coefficient of Variance -19.17 -10.41 -5.70 -10.68

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Nuvation Bio - NUVB

Date Name Shares Transaction Value
Oct 10, 2024 Philippe Sauvage Chief Financial Officer 750,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 26, 2024 Decheng Capital LLC Director 1,762,951 Open market or private purchase of non-derivative security Non-derivative transaction at $2.99 per share 5,271,223.49
Jun 26, 2024 Decheng Capital LLC Director 1,838,362 Open market or private purchase of non-derivative security Non-derivative transaction at $3 per share 5,515,086.00
Jun 26, 2024 Decheng Capital LLC Director 2,175,236 Open market or private purchase of non-derivative security Non-derivative transaction at $2.98 per share 6,482,203.28
Jun 14, 2024 Kim D. Blickenstaff Director 172,189 Open market or private purchase of non-derivative security Non-derivative transaction at $2.9 per share 499,348.10
May 30, 2024 Daniel G. Welch Director 293,203 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.74 per share 510,173.22
May 30, 2024 Daniel G. Welch Director 659,947 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.64 per share 1,082,313.08
May 30, 2024 Daniel G. Welch Director 19,547 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 30, 2024 Daniel G. Welch Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 12, 2024 Colleen Sjogren Chief Commercial Officer 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 12, 2024 Colleen Sjogren Chief Commercial Officer 250,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 12, 2024 Jun Yuan Wang CEO, ANHEART THERAPEUTICS LTD.; Director 388,299 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 12, 2024 Jun Yuan Wang CEO, ANHEART THERAPEUTICS LTD.; Director 486,669 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 12, 2024 Jun Yuan Wang CEO, ANHEART THERAPEUTICS LTD.; Director 550,758 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 12, 2024 Jun Yuan Wang CEO, ANHEART THERAPEUTICS LTD.; Director 1,378,989 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2024 David C. Hanley CHIEF TECHNICAL OPERATIONS 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2024 Stacy Markel CHIEF PEOPLE OFFICER 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2024 Gary Hattersley CHIEF SCIENTIFIC OFFICER 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2024 Dong Fang Liu CHIEF MEDICAL OFFICER 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2024 Kerry A. Wentworth CHIEF REGULATORY OFFICER 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Nuvation Bio in the News